Summary
This 2023 review in Microbiological Research examines Streptomyces spp.—a genus historically known for antibiotic production—as emerging candidate probiotic organisms for human health applications. The authors assess the mechanistic evidence for probiotic activity, including enzyme production and pathogen inhibition, whilst addressing genus-specific safety considerations. The work contributes to repositioning soil-derived actinobacteria within therapeutic microbiology and gut health contexts, though the evidence base for clinical translation remains to be fully established.
Regional applicability
As a mechanistic review rather than a field or clinical trial, this work has limited direct applicability to UK farming or clinical practice. However, it may inform future UK regulatory frameworks for novel probiotic licensing and soil microbe-derived therapeutic development.
Key measures
Probiotic mechanisms (enzyme activity, antimicrobial properties, immune response); safety profile relative to antibiotic production history
Outcomes reported
The review assessed the mechanistic basis for probiotic activity in Streptomyces spp., including enzyme production, pathogen inhibition and immunomodulation, whilst evaluating safety concerns specific to this actinobacterial genus.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.